Aytu Biopharma, Inc
AYTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385818
No open-market purchases or sales by Aytu Biopharma, Inc insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q2 2026, worth $8.25M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Aytu Biopharma, Inc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 32 | 1 | 33 | +2 |
| Shares | 3.42M | 10 | 3.58M | +164.2K (+4.8%) |
| Value | $7.45M | $22 | $6.73M | −$715.5K (−9.6%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Aytu Biopharma, Inc at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Diadema Partners LP | 272,670 | $512.6K | 0.36% |
| Persistent Asset Partners Ltd | 62,452 | $117.4K | 0.09% |
| Two Sigma Advisers, LP | 39,800 | $74.8K | 0.00% |
| Dimensional Fund Advisors LP | 30,964 | $58.2K | 0.00% |
| FMR LLC | 5 | $9 | 0.00% |
| Citigroup Inc | 1 | $2 | 0.00% |
Sold out (4)
Institutions that held Aytu Biopharma, Inc at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Kanen Wealth Management LLC | 573,358 | $1.25M |
| HRT Financial LP | 19,988 | $43.0K |
| Raymond James Financial Inc | 55 | $120 |
| Northwestern Mutual Wealth Management Co | 1 | $2 |
Not filed for Q3 2025 yet (1)
Institutions that held Aytu Biopharma, Inc at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Moser Wealth Advisors, LLC | 10 | $22 |